<code id='F41EDA4419'></code><style id='F41EDA4419'></style>
    • <acronym id='F41EDA4419'></acronym>
      <center id='F41EDA4419'><center id='F41EDA4419'><tfoot id='F41EDA4419'></tfoot></center><abbr id='F41EDA4419'><dir id='F41EDA4419'><tfoot id='F41EDA4419'></tfoot><noframes id='F41EDA4419'>

    • <optgroup id='F41EDA4419'><strike id='F41EDA4419'><sup id='F41EDA4419'></sup></strike><code id='F41EDA4419'></code></optgroup>
        1. <b id='F41EDA4419'><label id='F41EDA4419'><select id='F41EDA4419'><dt id='F41EDA4419'><span id='F41EDA4419'></span></dt></select></label></b><u id='F41EDA4419'></u>
          <i id='F41EDA4419'><strike id='F41EDA4419'><tt id='F41EDA4419'><pre id='F41EDA4419'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:leisure time    - browse:8742
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images

          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

          advertisement

          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment